Research supports the product candidate’s non-hormonal, non-systemic, rapidly-acting effects on autonomic biomarkers SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 26, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain

PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder is Complete; Topline results expected by calendar year end SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 13, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 10, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 5, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced

Topline results for the trial are expected by year end SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product

Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 29, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain

Posters Highlight New Insights into PH80’s Effects on Brain and Autonomic Activity SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 16, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 9, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced

Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of 2025 PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Vistagen continues to advance diverse intranasal pherine pipeline targeting

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 31, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today